Identification of an Orally Bioavailable,Brain-Penetrant Compound with Selectivity for the Cannabinoid Type 2 Receptor

Modulation of the endocannabinoid system (ECS) is of great interest for its therapeutic relevance in several pathophysiological processes. The CB2 subtype is largely localized to immune effectors, including microglia within the central nervous system, where it promotes anti-inflammation. Recently, a rational drug design toward precise modulation of the CB2 active site revealed the novelty of Pyrrolo[2,1-c][1,4]benzodiazepines tricyclic chemotype with a high conformational similarity in comparison to the existing leads. These compounds are structurally unique, confirming their chemotype novelty. In our continuing search for new chemotypes as selective CB2 regulatory molecules, following SAR approaches, a total of 17 selected (S,E)-11-[2-(arylmethylene)hydrazono]-PBD analogs were synthesized and tested for their ability to bind to the CB1 and CB2 receptor orthosteric sites. A competitive [³H]CP-55,940 binding screen revealed five compounds that exhibited >60% displacement at 10 μM concentration. Further concentration-response analysis revealed two compounds, 4k and 4q, as potent and selective CB2 ligands with sub-micromolar activities (K_i = 146 nM and 137 nM, respectively). In order to support the potential efficacy and safety of the analogs, the oral and intravenous pharmacokinetic properties of compound 4k were sought. Compound 4k was orally bioavailable, reaching maximum brain concentrations of 602 ± 162 ng/g (p.o.) with an elimination half-life of 22.9 ± 3.73 h. Whether administered via the oral or intravenous route, the elimination half-lives ranged between 9.3 and 16.7 h in the liver and kidneys. These compounds represent novel chemotypes, which can be further optimized for improved affinity and selectivity toward the CB2 receptor.     

The effect of shear controlled orientation in injection moulding on the mechanical properties of an aliphatic polyketone

This article relates to an investigation of injection moulding a new commercial polymer, an aliphatic polyketone (PK). A terpolymer and a 30% glass-filled grade were used as study materials together with an isotactic polypropylene that was used as a basis for comparison. Both conventional injection moulding and shear-controlled orientation injection moulding (SCORIM) were employed in processing. Tensile testing was carried out at 80°C as well as at room temperature. Polarized light microscopy and wide-angle x-ray diffraction were used in the characterization of the mouldings. An increase of up to 30% in Young's modulus and 35% in ultimate tensile strength, and a 70–90% increase in strain at peak were gained for the terpolymer (PK) at room temperature, as a result of SCORIM processing. A substantial improvement at 80°C was also recorded for unfilled SCORIM PK mouldings, and is attributed to the pronounced molecular alignment that was induced in SCORIM mouldings, as shown by Debye patterns. It is notable that the SCORIM mouldings of PK exhibit a greater tensile strength at 80°C than the SCORIM mouldings of isotactic polypropylene at 23°C. © 1997 John Wiley & Sons, Inc. J Polym Sci B: Polym Phys, 35: 415–430, 1997     

Bio-analytical methods for investigating the effect of age,body mass index and gender on the PK/PD ratio of antibiotics

The effectiveness of antibiotics (ABs) is governed by achieving the adequate pharmacokinetic (PK)/pharmacodynamics (PD) ratio. In this study, fast LC–MS/MS methods were developed and validated for the bioanalysis of cefaclor (CFC), ciprofloxacin (CFC), roxithomycin (RXM) and clindamycin (CLD). Chromatographic separation was performed on a C₁₈ Zorbax-Eclipse Plus (3.5 μm, 100 × 4.6 mm) using isocratic elution. Detection was performed by positive electrospray ionization. The methods were applied for the assessment of PK parameters in volunteers (n = 101, 64 male and 37 female) and the effects of age, body mass index (BMI) and gender were investigated. Good linearity (r ² ≥ 0.99), accuracy (>86%), precision (CV% ≤ 11) and extraction recovery (>83%) were observed for CFC, CFX, RXM and CLD. Application to PK studies revealed that age and BMI affected the T_half and the AUC of RXM and CLD (p < 0.023). Gender difference affected the critical PK parameters of the four ABs (T_half (U = 18; P = 0.036) of CFC, the C_max of CFX (U = 30; P = 0.017), the T_half (U = 23; P = 0.009) and AUC (U = 26; P = 0.008) of RXM and CLD), respectively. These results highlight the significance of age and BMI variations for RXM and CLD dosing. Furthermore, it indicates that the gender difference may be considered when adjusting the AB dose.     

Synthesis and cytotoxicity studies of novel anion‐exchanged Titanocene Y derivatives

Starting from the potential anticancer drug candidate Titanocene Y {bis‐[(4‐methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride}, anion exchange experiments were performed using silver malonate (1a) or silver cyclobutane‐1,1‐malonate (1b) in order to yield bis‐[(4‐methoxy‐benzyl)cyclopentadienyl] titanium(IV) malonate (2a) and bis‐[(4‐methoxy‐benzyl)cyclopentadienyl] titanium(IV) cyclobutane‐1,1‐malonate (2b). In addition, Titanocene Y was reacted with salicylic acid (3a) or 3,5‐dinitro‐salicylic acid (3b) in the presence of diethylamine to synthesize bis‐[(4‐methoxy‐benzyl)cyclopentadienyl] titanium(IV) salicylate (4a) or bis‐[(4‐methoxy‐benzyl)cyclopentadienyl] titanium(IV) 3,5‐dinitro‐salicylate (4b). These titanocenes had their cytotoxicity investigated through preliminary in vitro testing on the LLC‐PK (pig kidney epithelial) cell line in an MTT‐based assay in order to determine their IC50 values. Titanocenes 2a–b and 4a were found to have IC50 values of 74 ( ± 13) µM , 18 ( ± 5) µM and 49 ( ± 11) µM on the LLC‐PK cell line, while compound 4b was found to have lost all its cytotoxic activity on this cell line. Copyright © 2010 John Wiley & Sons, Ltd.     

Discovery and SAR Studies of Potent Modulators of BMI-1 Expression

In our efforts to identify molecules that selectively reduce the expression of BMI1, a stem cell gene, we discovered and characterized the first-in-class series of small molecules that modulate the expression of BMI1 protein in cancer cells. Structure–activity and structure–property relationships associated with this series were investigated through medicinal chemistry efforts. These studies revealed important structural features required for achieving anti-tumor activity and acceptable pharmacokinetic properties within this series. The 4-CF₃−Ph at the left-side of the molecule, a proper placement of the N-atom on the six-membered heterocycle in the middle, combined with a properly substituted C(2)-methyl benzimidazole on the right-hand side were required to achieve potency, microsomal stability, and exposure upon oral dosing. A compound (PTC-02) with acceptable pharmacological properties and efficacious in vivo in several tumor animal models was identified.